Daniel Stauder
Stock Analyst at Citizens Capital Markets
(1.50)
# 3,175
Out of 4,784 analysts
14
Total ratings
15.38%
Success rate
-1.56%
Average return
Main Sectors:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $3.77 | +85.68% | 1 | Mar 5, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $83.05 | +32.45% | 4 | Feb 28, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $534.95 | +35.53% | 1 | Feb 26, 2025 | |
| AORT Artivion | Reiterates: Market Outperform | $33 | $24.25 | +36.08% | 3 | Feb 25, 2025 | |
| ATRC AtriCure | Reiterates: Market Outperform | $60 | $31.83 | +88.50% | 4 | Feb 13, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $13.95 | - | 1 | May 7, 2024 |
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $3.77
Upside: +85.68%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $83.05
Upside: +32.45%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $534.95
Upside: +35.53%
Artivion
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $24.25
Upside: +36.08%
AtriCure
Feb 13, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $31.83
Upside: +88.50%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $13.95
Upside: -